Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6949)
All Articles published online
|
Publishing Process of This Article
|
Jun 26, 2022 (publication date) through May 6, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yang HH, Huang Y, Zhou XC, Wang RN. Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis. World J Clin Cases 2022; 10(18): 6091-6104 [PMID: 35949827 DOI: 10.12998/wjcc.v10.i18.6091] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i18/6091.htm |
| Number | Citing Articles |
| 1 |
Jessica Codesido, Lara García-Varela, Xurxo García-Otero, Sheila Bouzón-Barreiro, Noemí Gómez-Lado, Francisco José Toja-Camba, Cristina Mondelo-García, Héctor Lazaré, Julia Baguña Torres, Jana Vidal-Otero, Santiago Medin-Aguerre, Alejandro Sanchez-Crespo, Francisco J. Otero-Espinar, José R. Herance, Anxo Fernández-Ferreiro, Pablo Aguiar. PET biodistribution study of subcutaneous and intravenous administration of adalimumab in an inflammatory bowel disease model. International Journal of Pharmaceutics 2025; 669: 125011 doi: 10.1016/j.ijpharm.2024.125011
|
| 2 |
Ahmed Salman, Mohamed A Salman, Ahmed Elewa, Asmaa M Awwad. Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis. Cureus 2024; doi: 10.7759/cureus.61547
|
| 3 |
Eimear Foley, Ahmad Basirat, Ankit Yadav, Shane O'Brien, Patrick D. Mitchell, Seamas C. Donnelly. A case of pulmonary and cutaneous sarcoidosis. Breathe 2025; 21(2): 240228 doi: 10.1183/20734735.0228-2024
|
| 4 |
Nariman Hossein-Javaheri, Michael Youssef, Yaanu Jeyakumar, Vivian Huang, Parul Tandon. The Management of Inflammatory Bowel Disease during Reproductive Years: An Updated Narrative Review. Reproductive Medicine 2023; 4(3): 180 doi: 10.3390/reprodmed4030017
|
| 5 |
Nouran Alwisi, Rana Ismail, Hissa Al-Kuwari, Khalifa H. Al-Ansari, Mohammed A. Al-Matwi, Noor A. Aweer, Wejdan N. Al-Marri, Yousif Al-Kubaisi, Muneera Al-Mohannadi, Shahd Hamran, Suhail A. R. Doi, Habib H. Farooqui, Tawanda Chivese. Comparative Efficacy of Subcutaneous Versus Intravenous Interleukin 12/23 Inhibitors for the Remission of Moderate to Severe Crohn’s Disease: A Systematic Review and Meta-Analysis. Biomedicines 2025; 13(3): 702 doi: 10.3390/biomedicines13030702
|
| 6 |
Martina Tallarico, Caterina Palleria, Livia Ruffolo, Rocco Spagnuolo, Maria Diana Naturale, Adele Emanuela De Francesco, Caterina De Sarro, Rossella Romeo, Rita Citraro, Patrizia Doldo, Ludovico Abenavoli, Luca Gallelli, Francesco Luzza, Antonio Leo, Giovambattista De Sarro. Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study. Pharmaceutics 2022; 14(11): 2449 doi: 10.3390/pharmaceutics14112449
|
| 7 |
Arnaud Dominati, Christian Ascoli, Israel Rubinstein, Mark D. McCauley, Nadera J. Sweiss. Narrative review of adalimumab for the treatment of cardiac sarcoidosis. Heart Rhythm O2 2025; 6(3): 368 doi: 10.1016/j.hroo.2024.12.012
|
| 8 |
Mahmoud E. Kamal, Rehab H. Werida, Mahasen A. Radwan, Safaa R. Askar, Gamal A. Omran, Marwa A. El-Mohamdy, Radwa S. Hagag. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. Inflammopharmacology 2024; 32(5): 3259 doi: 10.1007/s10787-024-01508-w
|